Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2023-01-11 Board/Management Inform…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides appoints Holger Lembrer as Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release dated January 11, 2023, announcing the appointment of Holger Lembrer as the new Chief Financial Officer (CFO) of Oncopeptides AB, replacing the interim CFO. This content directly relates to changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information' (Code: MANG) is the most appropriate classification for announcements regarding changes in senior management.
2023-01-11 English
Oncopeptides utser Holger Lembrer till Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release dated January 11, 2023, announcing that Oncopeptides AB has appointed Holger Lembrer as the new Chief Financial Officer (CFO), replacing the interim CFO. This constitutes an announcement of a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (3050 chars), but it contains the full announcement content, not just a notice that a document is attached, making MANG the most appropriate classification over RPA or RNS.
2023-01-11 Swedish
Monica Shaw utsedd till vd för Oncopeptides – Jakob Lindberg antar rollen som Chief Scientific Officer
Board/Management Information Classification · 1% confidence The document is a press release dated January 4, 2023, announcing a significant change in senior management: Dr. Monica Shaw is appointed CEO, replacing Jakob Lindberg, who moves to Chief Scientific Officer. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2023-01-04 Swedish
Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer
Board/Management Information Classification · 1% confidence The document is a press release announcing a significant change in senior management: the appointment of Monica Shaw as CEO and Jakob Lindberg assuming the role of Chief Scientific Officer. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a full annual report (10-K), an earnings release (ER), or a transcript (CT).
2023-01-04 English
Oncopeptides provides update on Pepaxto US marketing authorization
Regulatory Filings Classification · 1% confidence The document is a press release dated December 07, 2022, providing an update on the US Food and Drug Administration's (FDA) request for the withdrawal of marketing authorization for the drug Pepaxto®. It discusses regulatory actions, clinical study outcomes (OCEAN study), and compares the US situation with European approvals (Pepaxti®). This content relates to significant legal/regulatory developments concerning a product, which aligns best with the 'Legal Proceedings Report' (LTR) category, as it details a major regulatory action impacting commercialization. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it details a regulatory action/decision impacting the company's product status, LTR is the most specific fit over the general 'RNS' fallback.
2022-12-07 English
Oncopeptides ger uppdatering om marknadsföringstillståndet för Pepaxto i USA
Legal Proceedings Report Classification · 1% confidence The document is a press release dated December 7, 2022, from Oncopeptides AB, written in Swedish. It announces an update regarding the marketing authorization status of their drug Pepaxto in the USA, specifically that the FDA requested its withdrawal based on Phase 3 study results (OCEAN). It also mentions the status of the drug in Europe (Pepaxti). This type of announcement, detailing regulatory actions, legal/clinical outcomes impacting the business, and providing context, fits best under 'Legal Proceedings Report' (LTR) if it were a lawsuit, but since it is a direct regulatory action concerning product approval/withdrawal, it is a significant corporate event announcement. Given the options, it is not a standard financial report (10-K, IR, ER, MRQ), nor is it a management change (MANG) or dividend notice (DIV). It is a specific regulatory/legal update concerning product status. Since it is a formal announcement about a regulatory decision impacting the business, and it is not a general regulatory filing fallback (RNS) or a report publication announcement (RPA), 'Legal Proceedings Report' (LTR) is the closest fit for significant regulatory/legal developments, although 'Regulatory Filings' (RNS) is also a possibility if LTR is strictly for lawsuits. However, regulatory actions concerning product status are often grouped with legal/regulatory updates. Given the context of FDA action, LTR is chosen over the general RNS fallback, as it details a specific regulatory challenge/outcome.
2022-12-07 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.